Xu-guang Yin

900 Chengnan Avenue
Shaoxing, 312000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Fully synthetic arecoline and arecaidine vaccine candidates with α-Galactosylceramide as built-in adjuvant.

Fully synthetic arecoline and arecaidine vaccine candidates with α-Galactosylceramide as built-in adjuvant.

Journal: European journal of medicinal chemistry

Published: May 07, 2026

A TLR7/8 agonist-chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development.

A TLR7/8 agonist-chitosan conjugate as an adjuvant for carbohydrate-based anticancer vaccine development.

Journal: Chemical communications (Cambridge, England)

Published: August 29, 2025

A conjugate vaccine strategy that induces protective immunity against arecoline.

A conjugate vaccine strategy that induces protective immunity against arecoline.

Journal: European journal of medicinal chemistry

Published: December 11, 2023

Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2.

Self-Adjuvanting Protein Vaccine Conjugated with a Novel Synthetic TLR4 Agonist on Virus-Like Liposome Induces Potent Immunity against SARS-CoV-2.

Journal: Journal of medicinal chemistry

Published: January 10, 2023

Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern.

Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern.

Journal: ACS infectious diseases

Published: June 24, 2022

A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern.

A protein vaccine with Alum/c-GAMP/poly(I:C) rapidly boosts robust immunity against SARS-CoV-2 and variants of concern.

Journal: Chemical communications (Cambridge, England)

Published: March 04, 2022

MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.

MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.

Journal: Journal of medicinal chemistry

Published: February 02, 2022

Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern.

Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern.

Journal: Journal of medicinal chemistry

Published: January 24, 2022

RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern.

RBD conjugate vaccine with a built-in TLR1/2 agonist is highly immunogenic against SARS-CoV-2 and variants of concern.

Journal: Chemical communications (Cambridge, England)

Published: January 18, 2022

Synthesis and Evaluation of Liposomal Anti-GM3 Cancer Vaccine Candidates Covalently and Noncovalently Adjuvanted by αGalCer.

Synthesis and Evaluation of Liposomal Anti-GM3 Cancer Vaccine Candidates Covalently and Noncovalently Adjuvanted by αGalCer.

Journal: Journal of medicinal chemistry

Published: February 04, 2021

Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.

Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.

Journal: Chemistry, an Asian journal

Published: April 02, 2019

Peptide-free Synthetic Nicotine Vaccine Candidates with α-Galactosylceramide as Adjuvant.

Peptide-free Synthetic Nicotine Vaccine Candidates with α-Galactosylceramide as Adjuvant.

Journal: Molecular pharmaceutics

Published: March 02, 2019

Showing 1-12 of 14

Last Updated: 09/26/2026